Phase two of clinical gout trial begins at UAB

The University of Alabama Division of Clinical Immunology and Rheumatology has started on phase two of a proof-of-concept clinical trial, evaluating the use of immunomodulator mycophenolate mofetil, or MMF, with Horizon Pharma plc's KRYSTEXXA drug in order to lower the uric acid levels for people living with uncontrolled gout.   The trial will consist of a double-blind operation, with a placebo-controlled phase two trial, designed to evaluate whether a 12-week course of immune-modulating therapy…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news